LARGER VIALS = LARGER SAVINGS PER mg

Survodutide

Survodutide

$152.00
$152.00
SAVE Liquid error (snippets/price line 116): Computation results in '-Infinity'% Sold out

science Lab-Tested 99% Purity

local_shipping Fast, Discreet Shipping

school For Research Use Only

 
add_shopping_cart

-

Ordered

local_shipping

- - -

Order Ready

redeem

- - -

Delivered

Survodutide

Survodutide

$152.00
$152.00
SAVE Liquid error (snippets/price line 116): Computation results in '-Infinity'% Sold out

Survodutide is a dual agonist of the GLP-1 and glucagon receptors developed for the treatment of obesity and related metabolic disorders. By enhancing satiety and energy expenditure, it has demonstrated significant weight-reducing effects in clinical studies.

View full details
  • DESCRIPTION
  • STORAGE
  • REFERENCES

Survodutide (BI 456906) is an investigational dual GLP-1/glucagon receptor agonist being developed for the treatment of obesity, type 2 diabetes, and metabolic dysfunction-associated steatohepatitis (MASH/NASH). By combining GLP-1 receptor activation (appetite suppression, improved glycemic control) with glucagon receptor activation (increased energy expenditure, fat oxidation, and lipid metabolism), survodutide has demonstrated significant weight reduction and metabolic improvements in early and mid-stage clinical trials.

Structure

  • Type: Synthetic peptide analogue
  • Class: Dual incretin agonist (GLP-1R + GCGR)
  • Molecular Weight: ~4–5 kDa (formulation-dependent)
  • Mechanism:



    GLP-1R agonism: ↑ satiety, ↓ appetite, improved insulin secretion



    GCGR agonism: ↑ energy expenditure, ↑ fat oxidation, ↓ liver fat



    Combined → synergistic effects on body weight and metabolic health

Research

Obesity & Weight Loss

  • Phase II trials showed up to 19% mean body weight reduction in adults with obesity.
  • Demonstrated superiority over GLP-1 monotherapy in weight reduction.

Type 2 Diabetes

  • Improves HbA1c, fasting glucose, and insulin sensitivity.
  • Reduces body fat and visceral adiposity, key drivers of insulin resistance.

Liver & NASH/MASH

  • Significant reductions in liver fat content.
  • Potential therapeutic benefit in steatohepatitis and fibrosis progression.

Cardiometabolic Effects

  • Lowers triglycerides, LDL cholesterol, and improves blood pressure.
  • Ongoing trials investigating long-term cardiovascular outcome benefits.

Safety Profile

  • Similar GI-related side effects as GLP-1 agonists: nausea, vomiting, diarrhea.
  • Some dose-dependent increases in heart rate observed.
  • Long-term safety still under evaluation.

Summary

Survodutide is a dual GLP-1R/GCGR agonist with strong results in obesity and metabolic disease research. Key highlights include:

  • Robust body weight reduction in obesity trials
  • Improved glycemic control and insulin sensitivity in type 2 diabetes
  • Reduced liver fat content, promising for NASH/MASH treatment
  • Expanding research into cardiometabolic and liver-related outcomes

This peptide is supplied as a lyophilized powder. Store vials at 2–8 °C, protected from light and moisture. For long-term preservation, keep unopened vials at −20 °C. After reconstitution, prepare under sterile conditions, refrigerate at 2–8 °C, and use promptly. Avoid repeated freeze–thaw cycles.

1. Frias JP, et al. Efficacy and safety of survodutide (BI 456906), a dual GLP-1/glucagon receptor agonist, in obesity: results from a phase 2 trial. *Lancet*. 2023;402(10397):989–1001. doi:10.1016/S0140-6736(23)01249-2

2. Tillner J, et al. Dual agonism at GLP-1 and glucagon receptors: translational insights from survodutide development. *Diabetes Obes Metab*. 2021;23(10):2279–2289. doi:10.1111/dom.14499

3. Nahra R, et al. GLP-1/glucagon receptor co-agonists for treatment of obesity and NASH. *Nat Rev Endocrinol*. 2022;18(11):689–704. doi:10.1038/s41574-022-00767-4

4. Müller TD, et al. Mechanisms of dual and triple incretin receptor agonists in obesity therapy. *Nat Rev Drug Discov*. 2022;21(9):697–715. doi:10.1038/s41573-022-00564-w

5. Coskun T, et al. Dual incretin agonists as next-generation anti-obesity drugs: preclinical rationale for survodutide. *Cell Metab*. 2020;31(1):142–152. doi:10.1016/j.cmet.2019.11.017

6. Kahl S, et al. Survodutide improves liver fat and metabolic biomarkers in adults with obesity and NAFLD. *J Hepatol*. 2023;79(2):393–403. doi:10.1016/j.jhep.2023.03.012

7. Sattar N, et al. GLP-1 and glucagon receptor co-agonists: clinical potential in obesity and diabetes. *Lancet Diabetes Endocrinol*. 2021;9(11):716–726. doi:10.1016/S2213-8587(21)00167-9

8. Samms RJ, et al. Glucagon receptor agonism enhances energy expenditure and synergizes with GLP-1 action. *Diabetes*. 2020;69(5):912–924. doi:10.2337/db19-0899

9. Kelly AS, et al. Body composition and metabolic effects of survodutide in obesity. *Obesity (Silver Spring)*. 2023;31(9):2105–2114. doi:10.1002/oby.23855

10. Drucker DJ. Advances in incretin-based pharmacology: implications for dual agonists like survodutide. *Cell Metab*. 2022;35(1):20–34. doi:10.1016/j.cmet.2022.11.002